Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Non-cash Items (2016 - 2025)

Ptc Therapeutics has reported Non-cash Items over the past 10 years, most recently at $210.7 million for Q4 2025.

  • Quarterly results put Non-cash Items at $210.7 million for Q4 2025, up 2978.16% from a year ago — trailing twelve months through Dec 2025 was $210.7 million (up 2978.16% YoY), and the annual figure for FY2025 was $210.7 million, up 2978.16%.
  • Non-cash Items for Q4 2025 was $210.7 million at Ptc Therapeutics, up from $6.1 million in the prior quarter.
  • Over the last five years, Non-cash Items for PTCT hit a ceiling of $210.7 million in Q4 2025 and a floor of $4.8 million in Q1 2021.
  • Median Non-cash Items over the past 5 years was $7.2 million (2022), compared with a mean of $27.7 million.
  • Biggest five-year swings in Non-cash Items: crashed 95.96% in 2021 and later soared 2978.16% in 2025.
  • Ptc Therapeutics' Non-cash Items stood at $50.6 million in 2021, then decreased by 24.2% to $38.3 million in 2022, then crashed by 80.04% to $7.7 million in 2023, then fell by 10.54% to $6.8 million in 2024, then soared by 2978.16% to $210.7 million in 2025.
  • The last three reported values for Non-cash Items were $210.7 million (Q4 2025), $6.1 million (Q3 2025), and $6.5 million (Q2 2025) per Business Quant data.